10.69
3.17%
-0.35
Instil Bio Inc stock is currently priced at $10.69, with a 24-hour trading volume of 4,805.
It has seen a -3.17% decreased in the last 24 hours and a -1.20% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $11.03 pivot point. If it approaches the $10.48 support level, significant changes may occur.
Previous Close:
$11.04
Open:
$11.02
24h Volume:
4,805
Market Cap:
$69.53M
Revenue:
-
Net Income/Loss:
$-156.09M
P/E Ratio:
-7.5282
EPS:
-1.42
Net Cash Flow:
$-102.69M
1W Performance:
-3.13%
1M Performance:
-1.20%
6M Performance:
+3,055%
1Y Performance:
+1,682%
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
240-676-3715
Address
3963 Maple Avenue, Suite 350, Dallas
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
Nov-01-22 | Downgrade | Truist | Buy → Hold |
Aug-13-21 | Initiated | Robert W. Baird | Outperform |
Apr-13-21 | Initiated | Cowen | Outperform |
Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update - The Globe and Mail
The Globe and Mail
Instil Bio to Present at the Jefferies Virtual Healthcare Conference - The Globe and Mail
The Globe and Mail
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ... - The Globe and Mail
The Globe and Mail
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference - The Globe and Mail
The Globe and Mail
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL) - The Globe and Mail
The Globe and Mail
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on ... - The Globe and Mail
The Globe and Mail
Instil Bio Inc Stock (TIL) Financials Data
Instil Bio Inc (TIL) Net Income 2024
TIL net income (TTM) was -$156.09 million for the quarter ending December 31, 2023, a +30.06% increase year-over-year.
Instil Bio Inc (TIL) Cash Flow 2024
TIL recorded a free cash flow (TTM) of -$102.69 million for the quarter ending December 31, 2023, a +61.21% increase year-over-year.
Instil Bio Inc (TIL) Earnings per Share 2024
TIL earnings per share (TTM) was -$24.00 for the quarter ending December 31, 2023, a +30.23% growth year-over-year.
About Instil Bio Inc
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Cap:
|
Volume (24h):